So far, FDA-approved antibody-based approaches in sarcoma like PD-1/PDL-1 checkpoint inhibition (Dostarlimab and Pembrolizumab) or Denosumab for treatment of a subset of bone sarcomas are restricted to a minority of patients (8). This evidence concerns the gene CD274 and bone sarcoma.